Cite
HARVARD Citation
Hofman, M. et al. (2018). [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet oncology. 19 (6), pp. 825-833. [Online].